|Videos|May 20, 2017

The Risks and Benefits of Prescribing Antibiotics

Lauri A. Hicks, DO, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention, discusses the importance of preserving the effectiveness of antibiotics.

Lauri A. Hicks, DO, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention, discusses the importance of preserving the effectiveness of antibiotics.

Interview Transcript (slightly modified for readability)

“One thing that I think is really important, no matter who the prescriber is, is that the prescriber think about the risks and benefits of prescribing that antibiotic. For many, many years, we’ve thought of antibiotics as the quick-fix to, pretty much, any infection. What we’ve learned, over the years, is that there are actual severe consequences associated with treating antibiotics without respect.

What I’m proposing is that we really need to be taking antibiotic treatment more seriously. When we talk to our patients about antibiotics we need to really be communicating about both the risks and benefits of antibiotics.

I like to think of antibiotics as a natural resource that is in limited supply. We really should be thinking about opportunities to preserve the effectiveness of these life-saving drugs, so that when our children need them, when our parents need them, for serious infections, that they will actually work.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.